Comparative Pharmacology
Head-to-head clinical analysis: AZACITIDINE versus DACOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZACITIDINE versus DACOGEN.
AZACITIDINE vs DACOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Azacitidine is a pyrimidine nucleoside analog of cytidine that inhibits DNA methyltransferase, leading to hypomethylation of DNA and direct cytotoxicity on abnormal hematopoietic cells in bone marrow. It incorporates into RNA and DNA, causing disruption of nucleic acid metabolism and apoptosis.
Decitabine is a hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, resulting in hypomethylation of DNA and subsequent gene reactivation.
75 mg/m² subcutaneously or intravenously once daily for 7 days every 28 days.
15 mg/m² intravenously over 3 hours every 8 hours for 3 consecutive days, repeated every 6 weeks for a minimum of 4 cycles.
None Documented
None Documented
Clinical Note
moderateAzacitidine + Digoxin
"Azacitidine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAzacitidine + Digitoxin
"Azacitidine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAzacitidine + Deslanoside
"Azacitidine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateAzacitidine + Acetyldigitoxin
"Azacitidine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life approximately 4 hours (subcutaneous or intravenous); reflects rapid deamination by cytidine deaminase.
Terminal elimination half-life: approximately 1.5 hours at steady state. Short half-life necessitates daily administration in current regimens.
Renal (primarily as metabolites, ~50-85% of administered dose within 72 hours); fecal/biliary negligible.
Renal excretion of unchanged drug and metabolites: approximately 90% of total clearance. Biliary/fecal excretion: <10%.
Category C
Category C
Hypomethylating Agent
Hypomethylating Agent